Celldex Therapeutics CLDX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's operating cash flow?
- Celldex Therapeutics (CLDX) reported operating cash flow of -$65.59M in Q1 2026.
- How has Celldex Therapeutics's operating cash flow changed year-over-year?
- Celldex Therapeutics's operating cash flow decreased by 20.6% year-over-year, from -$54.37M to -$65.59M.
- What is the long-term trend for Celldex Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Celldex Therapeutics's operating cash flow has grown at a 36.4% compound annual growth rate (CAGR), from -$60.91M to -$210.95M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.